The article below I wrote 8 years ago, but it has relevance to today. I describe some of the tricks that were pulled when a pandemic vaccine was rushed into use in 2009, and how the agencies that rushed it covered their tracks over the next several years–Meryl
Saturday, August 4, 2012
- Since then, the H1N1 swine flu virus has remained in circulation, and we have continued to have fewer reported flu deaths in the US and abroad than in prior, recent years.
- Children, lacking prior immunity, were said to be at terrible risk–but then it turned out that although there were 2-3 times as many pediatric flu deaths in 2009-10 as during an average season, the flu season lasted much longer than usual. CDC reported 133 child flu deaths in 2008-9, 282 in 2009-10, 122 in 2010-11 and 33 in 2011-12.
- We were in dire need of vaccines, so it was said. Therefore a bizarre vaccine approval process was instituted.
… some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
The clinical trials on which approval was based involved more than 6,000 people for each vaccine, each of whom received a version which was basically the same as the one to be rolled out, but originally contained an avian flu (H5N1) strain – which had been expected to cause a pandemic – instead of H1N1.
Today’s research and a Canadian study looking at the vaccine’s effect on Guillain-Barre syndrome, a disorder in which the body attacks its nervous system, shows the shot is safe and should be used as a precaution to prevent infection, he said.
Although no estimates of symptomatic case fatality ratios were available from Africa and southeast Asia, a disproportionate number of estimated pandemic deaths might have occurred in these regions.
Human infection with H1N1 has generally resulted in low mortality, although certain subgroups… have significantly higher risk of severe disease.
The authors were able to dismiss the high birth defect rate by selecting a control group with a higher than expected rate, and by using groups small enough that the 0.91% increased rate in the vaccinated cohort was not statistically significant.
Anders Hviid, the last author on the study, was involved in an earlier study that was not sufficiently powered to detect a 2.7-fold increase in GBS following swine flu vaccinations. He was then able to conclude that “The risk of occurrence of Guillain-Barré syndrome is not increased after pandemic influenza vaccine.”